The recent Combi-v [1] and Combi-d [2,3], phase III
randomized trials, showed, respectively, an OS benefit
with Dabrafenib/Trametinib combination versus Vemurafenib
and an improvement in PFS and ORR with the
same combination versus Dabrafenib alone, in BRAF
V600E/K mutation positive metastatic or unresectable
cutaneous melanoma. We report the case of a young
patient with metastatic melanoma treated with anti-
BRAF/antiMEK combination